蓝帆医疗2025年预亏6.5亿-8.5亿 同步需补缴税款超1.69亿元

Core Viewpoint - Bluefan Medical (002382.SZ) is experiencing a significant increase in losses for the year 2025, alongside a substantial tax payment obligation, indicating ongoing challenges in its operational performance [3][10]. Financial Performance - The company forecasts a net loss of between 650 million yuan and 850 million yuan for 2025, a notable increase from the 446 million yuan loss reported in 2024 [4][11]. - The projected loss excluding non-recurring items is expected to be between 780 million yuan and 980 million yuan, compared to a loss of approximately 479 million yuan in the previous year [4][11]. - Basic earnings per share are anticipated to be a loss of 0.65 to 0.85 yuan per share, worsening from a loss of 0.44 yuan per share in the prior year [4][11]. Factors Influencing Performance - The losses are attributed to multiple factors, including fluctuations in international trade, pressure on product sales prices, and fixed asset impairments [4][11]. - Despite achieving a positive gross margin in the fourth quarter of 2025, the overall performance for the year remains significantly negative due to the aforementioned issues [4][11]. Tax Payment Obligations - Bluefan Medical is required to pay a total of 169.56 million yuan in tax payments due to special tax adjustments related to cross-border transactions from 2020 to 2022, with additional interest charges [5][12]. - The total tax payment and interest amount to 195.86 million yuan, with a remaining balance of 140.88 million yuan expected to impact the 2025 net profit [5][12]. Business Segment Performance - The cardiovascular and cerebrovascular division of the company is showing strong growth, with projected sales revenue of approximately 1.4 billion yuan in 2025, representing a year-on-year increase of over 24% [7][15]. - This division has successfully turned profitable and is becoming a significant support for the company's overall business development [7][15]. Additional Notes - The tax payment issue does not involve prior accounting errors or adjustments to previous financial data, nor does it entail any tax administrative penalties, ensuring that the company's normal operations remain unaffected [14].